DexCom Inc (DXCM)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $31.08B
Last updated: Nov 17, 2026 at 11:05 AM ET
DexCom Inc (DXCM) Stock Forecast
Analysts expect DexCom (DXCM) to earn $2.70 per share in the fiscal year ending Dec 31, 2026, on revenue of $5.23B. Of 29 analysts, 26 rate the stock Buy or Strong Buy, 3 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $3.13.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 29 ratings average 1.97, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 90% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 4 | 13.8% |
| Buy | 22 | 75.9% |
| Hold | 3 | 10.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 29
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 15.9% and revenue estimates rise 10.3%.
- Fiscal year ending Dec 31, 2026
- $2.70
- EPS consensus, revenue $5.23B
- Fiscal year ending Dec 31, 2027
- $3.13
- EPS consensus, revenue $5.77B
- Next report
- Feb 10, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.70 | $2.45 to $2.78 | 25 | $5.23B | $5.21B to $5.25B | 27 |
| Dec 31, 2027 | $3.13 | $2.76 to $3.46 | 25 | $5.77B | $5.71B to $5.90B | 27 |
Quarterly Estimates
The EPS consensus falls from $0.73 for the quarter ending Dec 31, 2026 to $0.64 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.73 | $0.66 to $0.84 | 28 | $1.41B | $1.33B to $1.48B | 28 |
| Mar 31, 2027 | $0.64 | $0.57 to $0.74 | 17 | $1.31B | $1.29B to $1.33B | 17 |
Estimate Revisions
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Quarter ending Mar 31, 2027 | 2 | 5 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 1.1% from $2.67.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $2.70 | $2.67 | $2.66 | $2.66 | $2.67 | +1.3% |
| Fiscal year ending Dec 31, 2027 | $3.13 | $3.13 | $3.12 | $3.13 | $3.13 | +0.2% |
| Quarter ending Mar 31, 2027 | $0.64 | $0.64 | $0.64 | $0.64 | $0.64 | -1.0% |
Frequently Asked Questions About DXCM
What is the DXCM stock forecast?
Consensus analyst estimates put DexCom's EPS at $2.70 for the fiscal year ending Dec 31, 2026, on revenue of $5.23B. The consensus rating from 29 analysts is Buy.
How do analysts rate DXCM stock?
Of 29 analysts covering DexCom, 4 rate it Strong Buy, 22 Buy, 3 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from DXCM next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $2.70, with estimates from $2.45 to $2.78 from 25 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $3.13, with estimates from $2.76 to $3.46 from 25 analysts.
What revenue do analysts expect from DexCom next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $5.23B, with estimates from $5.21B to $5.25B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $5.77B, with estimates from $5.71B to $5.90B.
How many analysts cover DXCM?
29 analysts rate DexCom stock, and 25 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
DXCM pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors